Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
06.01. | Marpai announces second tranche of growth funding with up to $5M from JGB | 3 | Seeking Alpha | ||
06.01. | Marpai, Inc. - 8-K, Current Report | - | SEC Filings | ||
23.12.24 | Marpai, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
10.12.24 | Marpai, Inc. - 8-K, Current Report | - | SEC Filings | ||
09.12.24 | Marpai-Präsident John Paul Powers kauft Aktien im Wert von 11.299 US-Dollar | 2 | Investing.com Deutsch | ||
09.12.24 | Marpai-Direktor Eitan Yaron investiert 124.999 US-Dollar in Unternehmensaktien | 3 | Investing.com Deutsch | ||
05.12.24 | Marpai announces pricing of $700,000 private placement | 2 | Seeking Alpha | ||
MARPAI Aktie jetzt für 0€ handeln | |||||
12.11.24 | Marpai, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
11.11.24 | Marpai GAAP EPS of -$0.30, revenue of $7.01M | 2 | Seeking Alpha | ||
11.11.24 | Marpai Reports Third Quarter 2024 Financial Results | 54 | PR Newswire | Turnaround continues to gain traction
TAMPA, Fla., Nov. 11, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX: MRAI), a technology platform... ► Artikel lesen | |
03.09.24 | Marpai, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.08.24 | Earnings call: Marpai reports Q2 2024 financial results and turnaround progress | 1 | Investing.com | ||
07.08.24 | Marpai Reports Second Quarter 2024 Financial Results | 111 | PR Newswire | Company continues to drive towards profitability
TAMPA, Fla., Aug. 7, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX: MRAI), a technology platform company, which operates... ► Artikel lesen | |
31.05.24 | Delisting of Securities of RiskOn International, Inc.; Graphjet Technology; Agile Therapeutics, Inc.; NextPlay Technologies, Inc.; Relativity Acquisition Corp.; iSun, Inc.; Ace Global Business Acquisition Limited; and Marpai, Inc. from The Nasdaq Stock Ma | 375 | GlobeNewswire (Europe) | NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of RiskOn International, Inc. RiskOn International, Inc.'s securities were suspended... ► Artikel lesen | |
24.05.24 | Marpai Announces Withdrawal From Nasdaq Hearings Process And Will Transition Trading To The OTCQX Market | 669 | PR Newswire | Move reduces cost and burdens of Nasdaq listing
TAMPA, Fla., May 24, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (Nasdaq: MRAI), an independent national Third-Party Administration... ► Artikel lesen | |
09.05.24 | Marpai Reports First Quarter 2024 Financial Results | 120 | PR Newswire | Reduces Operating Expense by over $5 million and Net Loss by over 50% compared to 2023
TAMPA, Fla., May 9, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (Nasdaq: MRAI), an independent... ► Artikel lesen | |
26.03.24 | Marpai Reports Fourth Quarter And Full Year 2023 Financial Results | 125 | PR Newswire | Full Year Benefit of Maestro Acquisition and Q4 Corrective Actions Driving Financial Improvement
TAMPA, Fla., March 26, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (Nasdaq: MRAI)... ► Artikel lesen | |
06.03.24 | Marpai Announces Preliminary Unaudited Financial Results For Fourth Quarter And Full Year 2023 | 119 | PR Newswire | Full Year Impact of Maestro Acquisition and Q4 Corrective Actions Driving Improvement
TAMPA, Fla., March 6, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (Nasdaq: MRAI), an independent... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
FRESENIUS | 36,920 | -0,70 % | UBS stuft Fresenius SE auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Fresenius mit einem Kursziel von 40 Euro auf "Buy" belassen. Die Bad Homburger müssten erklären, wie sie dem Gegenwind durch... ► Artikel lesen | |
TELADOC HEALTH | 9,888 | -1,22 % | Teladoc Health, Inc.: Teladoc Health to Announce Fourth Quarter 2024 Financial Results | ||
NUGEN MEDICAL DEVICES | 0,039 | -4,39 % | Unglaubliche News! Der Super-CEO der alle Türen öffnen kann! | ||
ATOSSA THERAPEUTICS | 0,806 | -0,74 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591 | SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment... ► Artikel lesen | |
CO-DIAGNOSTICS | 0,690 | -1,43 % | Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results | SALT LAKE CITY, Nov. 7, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development... ► Artikel lesen | |
LOGICMARK | 1,040 | 0,00 % | LogicMark, Inc. Announces Reverse Stock Splits | LOUISVILLE, Ky., Nov. 15, 2024 (GLOBE NEWSWIRE) -- LogicMark, Inc. (Nasdaq: LGMK) (the "Company"), a provider of personal emergency response systems (PERS), health communications devices, and technology... ► Artikel lesen | |
ASSURANCE HEALTHCARE | 0,026 | 0,00 % | ASSURANCE HEALTHCARE LIMITED: GENERAL ANNOUNCEMENT::MINUTES OF EXTRAORDINARY GENERAL MEETING HELD ON 03 JANUARY 2025 | ||
NAYA BIOSCIENCES | 0,461 | 0,00 % | NAYA Biosciences, Inc.: NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody | • PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla.... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 53,62 | -0,78 % | UBS stuft Siemens Healthineers auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Siemens Healthineers mit einem Kursziel von 53 Euro auf "Neutral" belassen. Die Bayern müssten das Risiko für ihre Jahresziele... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 47,180 | -0,86 % | UBS stuft FMC FRESENIUS MEDICAL CARE AG & CO KGAA auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für FMC mit einem Kursziel von 39 Euro auf "Neutral" belassen. Beim Dialysekonzern gehe es vor allem um die Marge, schrieb Analyst... ► Artikel lesen | |
GERRESHEIMER | 67,40 | +1,58 % | EQS-PVR: Gerresheimer AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Gerresheimer AG
Gerresheimer AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
03.02.2025 / 16:53 CET/CEST
Veröffentlichung... ► Artikel lesen | |
CARL ZEISS MEDITEC | 57,80 | +0,09 % | UBS stuft CARL ZEISS MEDITEC AG auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Carl Zeiss Meditec mit einem Kursziel von 50 Euro auf "Neutral" belassen. Mit Blick auf die Jenaer bräuchte es vor allem... ► Artikel lesen | |
GENEDX | 72,02 | 0,00 % | GeneDx Announces Preliminary 2024 Financial Results | STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for... ► Artikel lesen | |
ALIGNMENT HEALTHCARE | 15,460 | 0,00 % | Alignment Healthcare Reports Third Quarter 2024 Results | Reports $692.4 million in total revenue, up 51.6% year-over-year Increases Medicare Advantage membership, up 57.7% year-over-year to approximately 182,300 members, beating third-quarter and year-end... ► Artikel lesen | |
ECKERT & ZIEGLER | 55,70 | +1,74 % | EQS-News: Eckert & Ziegler SE: IT-Vorfall beeinträchtigt die Kommunikationskanäle der Eckert & Ziegler SE | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): Sonstiges
Eckert & Ziegler SE: IT-Vorfall beeinträchtigt die Kommunikationskanäle der Eckert & Ziegler SE
03.02.2025 / 13:23... ► Artikel lesen |